The combination of rapamycin and Sora synergistically inhibited the proliferation of CRC cells; furthermore, simultaneous treatment with rapamycin and Sora inhibited the growth of xenografts from CRC cells with mutations in KRAS and PIK3CA [31]. This evidence concerns the gene KRAS and colorectal carcinoma.